erythrosine has been researched along with Respiration Disorders in 1 studies
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.
Respiration Disorders: Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yannuzzi, LA | 1 |
| Rohrer, KT | 1 |
| Tindel, LJ | 1 |
| Sobel, RS | 1 |
| Costanza, MA | 1 |
| Shields, W | 1 |
| Zang, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography[NCT04674254] | Phase 4 | 43 participants (Actual) | Interventional | 2021-03-30 | Active, not recruiting | ||
| Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography[NCT03246152] | Phase 4 | 31 participants (Actual) | Interventional | 2017-10-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Correlation of BCVA change with degree of capillary non-perfusion before and after injections (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
| Intervention | Logmar (Mean) |
|---|---|
| Bevacizumab Group | -0.21 |
Effect of repeated intravitreal Anti-VEGF injections on Foveal Avascular Zone (FAZ) area measured using the freehand tool of ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
| Intervention | mm^2 (Mean) |
|---|---|
| Bevacizumab Group | 0.03 |
Effect of repeated intravitreal Anti-VEGF injections on macular capillary density using the change in the skeletonized vascular density and fractal dimension measured by ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
| Intervention | percentage of vascularity (Mean) |
|---|---|
| Bevacizumab Group | -2.5 |
1 review available for erythrosine and Respiration Disorders
| Article | Year |
|---|---|
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |